(Q37620332)

21 August 2017

1 reference

title

Predictors of treatment response in chronic hepatitis B. (English)

1 reference

21 August 2017

1 reference

Grace L-H Wong

1 reference

21 August 2017

Henry L-Y Chan

series ordinal

1 reference

21 August 2017

publication date

1 November 2009

1 reference

21 August 2017

1 reference

21 August 2017

1 reference

21 August 2017

1 reference

21 August 2017

page(s)

2167-2177

1 reference

A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11319850-000000000-00000

Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11319850-000000000-00000

Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11319850-000000000-00000

Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection

21 January 2018

2 references

https://api.crossref.org/works/10.2165%2F11319850-000000000-00000

21 January 2018

12 December 2020

A controlled trial of interferon with or without prednisone priming for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.2165%2F11319850-000000000-00000

Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D

21 January 2018

1 reference

12 December 2020

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

1 reference

12 December 2020

Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients

1 reference

12 December 2020

Durability of serologic response after lamivudine treatment of chronic hepatitis B.

1 reference

12 December 2020

Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a

1 reference

12 December 2020

1 reference

12 December 2020

Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma.

1 reference

12 December 2020

Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B.

1 reference

12 December 2020

Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection

1 reference

12 December 2020

Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group

1 reference

12 December 2020

Diagnosis, management, and treatment of hepatitis C: an update

1 reference

12 December 2020

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

1 reference

12 December 2020

Long-term remission of chronic hepatitis B after alpha-interferon therapy

1 reference

12 December 2020

Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase

1 reference

12 December 2020

Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology

1 reference

12 December 2020

Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP)

1 reference

12 December 2020

Clinical trial: effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B.

1 reference

12 December 2020

High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma

1 reference

12 December 2020

Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients.

1 reference

12 December 2020

Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma

1 reference

12 December 2020

Oral antivirals for chronic hepatitis B.

1 reference

12 December 2020

Virological response to different combination regimes of peginterferon alpha-2b and lamivudine in hepatitis B e antigen positive chronic hepatitis B

1 reference

12 December 2020

Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver

1 reference

12 December 2020

Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

1 reference

12 December 2020

Long-term follow-up of chronic hepatitis B patients treated with interferon alfa

1 reference

12 December 2020

Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B

1 reference

12 December 2020

Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature

1 reference

12 December 2020

Early hepatitis B virus DNA suppression can predict virologic response to peginterferon and lamivudine treatment

1 reference

12 December 2020

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

12 December 2020

Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.

1 reference

12 December 2020

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

1 reference

12 December 2020

Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B.

1 reference

12 December 2020

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group

1 reference

12 December 2020

HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma.

1 reference

12 December 2020

High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study

1 reference

12 December 2020

Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response

1 reference

12 December 2020

Four years of lamivudine treatment in Chinese patients with chronic hepatitis B.

1 reference

12 December 2020

Telbivudine versus lamivudine in patients with chronic hepatitis B

1 reference

12 December 2020

Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.

1 reference

12 December 2020

Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial

1 reference

12 December 2020

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

1 reference

12 December 2020

A review of the natural history of chronic hepatitis B in the era of transient elastography.

1 reference

12 December 2020

Treatment of patients with chronic hepatitis B who have failed previous antiviral treatment with pegylated interferon alpha2a (40 kda; PEGASYS).

1 reference

12 December 2020

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

1 reference

12 December 2020

Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine

1 reference

12 December 2020

Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response.

1 reference

12 December 2020

Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine

1 reference

12 December 2020

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

1 reference

12 December 2020

Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels

1 reference

12 December 2020

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

1 reference

12 December 2020

Serum HBsAg changes in HBeAg positive chronic hepatitis B patients with continuous viral load reductions during treatment with adefovir or peg-interferon-alpha-2a

1 reference

12 December 2020

Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1.

1 reference

12 December 2020

Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response

1 reference

12 December 2020

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

1 reference

12 December 2020

Treatment of chronic hepatitis B: focus on telbivudine

1 reference

12 December 2020

Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy

1 reference

12 December 2020

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

1 reference

12 December 2020

Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.

1 reference

12 December 2020

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

1 reference

12 December 2020

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

1 reference

12 December 2020

Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.

1 reference

12 December 2020

Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B.

1 reference

12 December 2020

Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa

1 reference

12 December 2020

HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B.

1 reference

12 December 2020

Antiviral drug resistance: clinical consequences and molecular aspects

1 reference

12 December 2020

Long-term lamivudine treatment is associated with a good maintained response in severe acute exacerbation of chronic HBeAg-negative hepatitis B

1 reference

12 December 2020

Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication

1 reference

12 December 2020

Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b

1 reference

12 December 2020

Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.

1 reference

12 December 2020

Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine

1 reference

12 December 2020

Hepatocellular carcinoma and hepatitis B virus

1 reference

12 December 2020

10.2165/11319850-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

21 August 2017

1026188609

0 references

1 reference